Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03792971 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects
A Phase 1 study, sponsored by Galera Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT03792971 is a Phase 1 study that has completed, run by Galera Therapeutics. The registered enrollment target is 13 participants.
The verdict
NCT03792971, a Phase 1 study, has completed, sponsored by Galera Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This will be a single center, phase 1, open-label, fixed-sequence study under fasting conditions to evaluate the effect of 90 mg intravenous (IV) infusions of GC4419 on the single-dose pharmacokinetic (PK) of dextromethorphan (DM) capsules liquid filled.
Interventions
- DRUG GC4419
- DRUG Dextromethorphan HBr
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-02-10 |
| Est. Completion | 2019-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03792971
The ClinicalTrials.gov registry entry for NCT03792971 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galera Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GC4419 is the first listed.
NCT03792971 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03792971 about?
NCT03792971 is a clinical study titled "Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects". This will be a single center, phase 1, open-label, fixed-sequence study under fasting conditions to evaluate the effect of 90 mg intravenous (IV) infusions of GC4419 on the single-dose pharmacokinetic (PK) of dextromethorphan (DM) capsules liquid filled.
What is the current status of trial NCT03792971?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2019-02-10. Estimated completion is 2019-02-15.
What interventions are being tested in trial NCT03792971?
The interventions under investigation include: GC4419 (DRUG), Dextromethorphan HBr (DRUG).
Who is sponsoring clinical trial NCT03792971?
This trial is sponsored by Galera Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.